Markwell Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 14 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 55.14%
- Profit Growth 39.07%
- Ebitda 36.97%
- Net Worth 36.15%
- Total Assets -3.22%
About Markwell Pharmaceuticals
Markwell Pharmaceuticals Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 November 2010 and has a history of 14 years and three months. Its registered office is in Agra, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rajeev Kumar, Deepak Mishra, Devendra Sharma, and One other member serve as directors at the Company.
Company Details
-
Location
Agra, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51101UP2010PTC042548
-
Company No.
042548
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Nov 2010
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Markwell Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeev Kumar
|
Director | 11-Nov-2010 | Current |
|
Deepak Mishra
|
Director | 11-Nov-2010 | Current |
|
Devendra Sharma
|
Director | 11-Nov-2010 | Current |
|
Sameer Sharma
|
Director | 11-Nov-2010 | Current |
Financial Performance of Markwell Pharmaceuticals.
Markwell Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 55.14% increase. The company also saw a substantial improvement in profitability, with a 39.07% increase in profit. The company's net worth Soared by an impressive increase of 36.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Markwell Pharmaceuticals?
In 2017, Markwell Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Markwell Pharmaceuticals?
Unlock and access historical data on people associated with Markwell Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Markwell Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Markwell Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.